Article (Scientific journals)
Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
Andre, Fabrice; Neven, Patrick; Marinsek, Nina et al.
2014In Current Medical Research and Opinion
Peer Reviewed verified by ORBi
 

Files


Full Text
Disease management patterns ....pdf
Author preprint (441.63 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
advanced breast cancer; chemotherapy; endocrine/hormone therapy; Europe; guideline
Abstract :
[en] Abstract Background: International guidelines for hormone-receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (BC) recommend sequential lines of hormonal therapy (HT), and only recommend chemotherapy for patients with extensive visceral involvement or rapidly progressive disease. This study evaluated actual physician-reported treatments for advanced BC in Europe. Methods: We conducted a retrospective chart review of 355 postmenopausal women with HR+, HER2- advanced BC who progressed on >/=1 line of HT (adjuvant or advanced) and completed >/=1 line of chemotherapy (advanced). Treatment choice was evaluated for each line of therapy. Results: Of 355 patients, 111 (31%) received first-line chemotherapy, whereas 218 (61%) and 26 (7%) switched from HT to chemotherapy in second and third line, respectively. More patients receiving first-line HT had bone metastases (73% vs 27% chemotherapy). Patients treated with first-line chemotherapy had more brain (12% vs 3% HT) or extensive liver (13% vs 6% HT) metastases. Subgroup analysis of 188 patients who received first-line HT and had de novo advanced BC or relapsed/recurrent disease more than 1 year after adjuvant therapy found that the majority (89%; n = 167) of these patients switched to chemotherapy in second line. However, among these 167 patients, 27% had no significant changes in metastases between first and second line. Among the 73% of patients who had significant changes in metastases, 20% had no brain metastases or extensive visceral disease. Conclusions: Our study suggests that the guideline-recommended use of multiple HT lines is open to interpretation and that optimal treatment for European postmenopausal women with HR+, HER2- advanced BC who responded to HT may not be achieved.
Disciplines :
Oncology
Author, co-author :
Andre, Fabrice
Neven, Patrick
Marinsek, Nina
Zhang, Jie
Baladi, Jean-Francois
Degun, Ravi
Benelli, Giancarlo
Saletan, Stephen
Jerusalem, Guy  ;  Université de Liège - ULiège > Département des sciences cliniques > Oncologie
Language :
English
Title :
Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
Publication date :
2014
Journal title :
Current Medical Research and Opinion
ISSN :
0300-7995
eISSN :
1473-4877
Publisher :
Taylor & Francis, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 28 February 2014

Statistics


Number of views
256 (10 by ULiège)
Number of downloads
536 (4 by ULiège)

Scopus citations®
 
40
Scopus citations®
without self-citations
35
OpenCitations
 
43

Bibliography


Similar publications



Contact ORBi